Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Females with cystic fibrosis have a larger decrease in sweat chloride in response to lumacaftor/ivacaftor compared to males.
Aalbers BL, Hofland RW, Bronsveld I, de Winter-de Groot KM, Arets HGM, de Kiviet AC, van Oirschot-van de Ven MMM, Kruijswijk MA, Schotman S, Michel S, van der Ent CK, Heijerman HGM. Aalbers BL, et al. Among authors: hofland rw. J Cyst Fibros. 2021 Jan;20(1):e7-e11. doi: 10.1016/j.jcf.2020.05.004. Epub 2020 May 21. J Cyst Fibros. 2021. PMID: 32448708 Free article.
Clinical effect of lumacaftor/ivacaftor in F508del homozygous CF patients with FEV1 ≥ 90% predicted at baseline.
Aalbers BL, de Winter-de Groot KM, Arets HGM, Hofland RW, de Kiviet AC, van Oirschot-van de Ven MMM, Kruijswijk MA, Schotman S, Michel S, van der Ent CK, Heijerman HGM. Aalbers BL, et al. Among authors: hofland rw. J Cyst Fibros. 2020 Jul;19(4):654-658. doi: 10.1016/j.jcf.2019.12.015. Epub 2020 Jan 7. J Cyst Fibros. 2020. PMID: 31924546 Free article.
Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes.
Barry PJ, Mall MA, Álvarez A, Colombo C, de Winter-de Groot KM, Fajac I, McBennett KA, McKone EF, Ramsey BW, Sutharsan S, Taylor-Cousar JL, Tullis E, Ahluwalia N, Jun LS, Moskowitz SM, Prieto-Centurion V, Tian S, Waltz D, Xuan F, Zhang Y, Rowe SM, Polineni D; VX18-445-104 Study Group. Barry PJ, et al. N Engl J Med. 2021 Aug 26;385(9):815-825. doi: 10.1056/NEJMoa2100665. N Engl J Med. 2021. PMID: 34437784 Free PMC article. Clinical Trial.
Radiological and long-term clinical response to elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease.
Aalbers BL, Mohamed Hoesein FAA, Hofland RW, Bronsveld I, Kruijswijk MA, Schotman S, Slingerland CW, Panhuis H, van der Ent CK, Heijerman HGM. Aalbers BL, et al. Among authors: hofland rw. Pediatr Pulmonol. 2023 Aug;58(8):2317-2322. doi: 10.1002/ppul.26486. Epub 2023 May 24. Pediatr Pulmonol. 2023. PMID: 37222401 Clinical Trial.
QuantiFERON-plus does not discriminate between active and latent tuberculosis.
Hofland RW, Bossink AWJ, Nierkens S, Paardekooper SPA, van den Broek BTA, Lammers JJ, van Haeften I, Thijsen SFT. Hofland RW, et al. Infect Dis (Lond). 2018 Jun;50(6):479-482. doi: 10.1080/23744235.2018.1425550. Epub 2018 Jan 15. Infect Dis (Lond). 2018. PMID: 29334817 No abstract available.
18 results